Viridian’s $150M offering; Surrozen scraps IBD drug candidate; Assembly ends deal with Indiana University

Plus, news about Vor Bio, Vaxxinity, Immatics and Certis Oncology:

Viridian Therapeutics’ $150M public offering: The Waltham, MA-based biotech is selling about 7.1 million shares of its common stock at $21.00 per share, expecting to bring in $150 million to help advance its clinical programs. Its…
Click here to view original post